학술논문
A prospective, observational study of fidaxomicin use for Clostridioides difficileinfection in France
Document Type
Article
Author
Guery, Benoit; Berger, Pierre; Gauzit, Remy; Gourdon, Magali; Barbut, Frédéric; group:, DAFNE study; Bémer, Pascale; Bessède, Emilie; Camou, Fabrice; Cattoir, Vincent; Couzigou, Carine; Descamps, Dominique; Dinh, Aurélien; Laurans, Caroline; Lavigne, Jean-Philippe; Lechiche, Catherine; Leflon-Guibout, Véronique; Le Monnier, Alban; Levast, Marion; Mootien, Joy Yoganaden; N’Guyen, Yohan; Piroth, Lionel; Prazuck, Thierry; Rogeaux, Olivier; Roux, Anne-Laure; Vachée, Anne; Vernet Garnier, Véronique; Wallet, Frédéric
Source
Journal of International Medical Research; June 2021, Vol. 49 Issue: 6
Subject
Language
ISSN
03000605; 14732300
Abstract
Objective To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficileinfection (CDI) treated with and without fidaxomicin.Methods This prospective, multicentre, observational study (DAFNE) enrolled hospitalised patients with CDI, including 294 patients treated with fidaxomicin (outcomes recorded over a 3-month period) and 150 patients treated with other CDI therapies during three 1-month periods. The primary endpoint was baseline and CDI characteristics of fidaxomicin-treated patients.Results At baseline, the fidaxomicin-treated population included immunocompromised patients (39.1%) and patients with severe (59.2%) and recurrent (36.4%) CDI. Fidaxomicin was associated with a high rate of clinical cure (92.2%) and low CDI recurrence (16.3% within 3 months). Clinical cure rates were ≥90% in patients aged ≥65 years, those receiving concomitant antibiotics and those with prior or severe CDI. There were 121/296 (40.9%) patients with adverse events (AEs), 5.4% with fidaxomicin-related AEs and 1.0% with serious fidaxomicin-related AEs. No fidaxomicin-related deaths were reported.Conclusions Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes. Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficileinfection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov.